Kymera Stock 130%: $135 Million Buy Boosts Immunology Bet
A major stake in Kymera Therapeutics highlights growing investor optimism in targeted protein degradation. This artic...
Thinking about hiring a financial advisor in your 20s? Discover key considerations to ensure you choose the right professional for you.
24,143 articlesA major stake in Kymera Therapeutics highlights growing investor optimism in targeted protein degradation. This artic...
Lucid Group has ambitious plans, but shifting from carmaker to tech supplier brings new risks. This article explains ...
A major hedge fund slashed its stake in Structure Therapeutics, prompting questions about the future path for GPCR-fo...
As AI tax prep tools surge this season, experts warn that convenience can come with risky gaps. taxpayers weigh speed...
Howard Lindzon’s work with StockTwits and Social Leverage reshapes how we think about investing in communities. This ...
When markets wobble, the strength of a company’s balance sheet and its cash runway often beat a glossy business story...
A hypothetical SpaceX Nasdaq move could quietly lift required minimum distributions for retirees. This piece breaks d...
The Pitt's latest season dives into a hospital cyberattack, a scenario many experts say echoes real-world risk in hea...
A disciplined, factor-based approach to gold miners may offer resilience as bullion eyes new highs. Here’s how the ET...
Constellation Energy trades below $290, prompting questions about value and risk. This guide breaks down the fundamen...
A fresh, practical look at Marek Capital’s investment playbook. Discover how MiB: Matt Cherwin, Co-Founder and CIO, s...
AI is reshaping memory demand, and Micron sits at the center. This long-form guide explains the bull case for micron ...